Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

TN. Rao, N. Hansen, J. Stetka, D. Luque Paz, M. Kalmer, J. Hilfiker, M. Endele, N. Ahmed, L. Kubovcakova, M. Rybarikova, H. Hao-Shen, F. Geier, C. Beisel, S. Dirnhofer, T. Schroeder, TH. Brümmendorf, D. Wolf, S. Koschmieder, RC. Skoda

. 2021 ; 137 (16) : 2139-2151. [pub] 20210422

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025838

We studied a subset of hematopoietic stem cells (HSCs) that are defined by elevated expression of CD41 (CD41hi) and showed bias for differentiation toward megakaryocytes (Mks). Mouse models of myeloproliferative neoplasms (MPNs) expressing JAK2-V617F (VF) displayed increased frequencies and percentages of the CD41hi vs CD41lo HSCs compared with wild-type controls. An increase in CD41hi HSCs that correlated with JAK2-V617F mutant allele burden was also found in bone marrow from patients with MPN. CD41hi HSCs produced a higher number of Mk-colonies of HSCs in single-cell cultures in vitro, but showed reduced long-term reconstitution potential compared with CD41lo HSCs in competitive transplantations in vivo. RNA expression profiling showed an upregulated cell cycle, Myc, and oxidative phosphorylation gene signatures in CD41hi HSCs, whereas CD41lo HSCs showed higher gene expression of interferon and the JAK/STAT and TNFα/NFκB signaling pathways. Higher cell cycle activity and elevated levels of reactive oxygen species were confirmed in CD41hi HSCs by flow cytometry. Expression of Epcr, a marker for quiescent HSCs inversely correlated with expression of CD41 in mice, but did not show such reciprocal expression pattern in patients with MPN. Treatment with interferon-α further increased the frequency and percentage of CD41hi HSCs and reduced the number of JAK2-V617F+ HSCs in mice and patients with MPN. The shift toward the CD41hi subset of HSCs by interferon-α provides a possible mechanism of how interferon-α preferentially targets the JAK2 mutant clone.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025838
003      
CZ-PrNML
005      
20211026133445.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2020005563 $2 doi
035    __
$a (PubMed)33667305
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rao, Tata Nageswara $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
245    10
$a JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality / $c TN. Rao, N. Hansen, J. Stetka, D. Luque Paz, M. Kalmer, J. Hilfiker, M. Endele, N. Ahmed, L. Kubovcakova, M. Rybarikova, H. Hao-Shen, F. Geier, C. Beisel, S. Dirnhofer, T. Schroeder, TH. Brümmendorf, D. Wolf, S. Koschmieder, RC. Skoda
520    9_
$a We studied a subset of hematopoietic stem cells (HSCs) that are defined by elevated expression of CD41 (CD41hi) and showed bias for differentiation toward megakaryocytes (Mks). Mouse models of myeloproliferative neoplasms (MPNs) expressing JAK2-V617F (VF) displayed increased frequencies and percentages of the CD41hi vs CD41lo HSCs compared with wild-type controls. An increase in CD41hi HSCs that correlated with JAK2-V617F mutant allele burden was also found in bone marrow from patients with MPN. CD41hi HSCs produced a higher number of Mk-colonies of HSCs in single-cell cultures in vitro, but showed reduced long-term reconstitution potential compared with CD41lo HSCs in competitive transplantations in vivo. RNA expression profiling showed an upregulated cell cycle, Myc, and oxidative phosphorylation gene signatures in CD41hi HSCs, whereas CD41lo HSCs showed higher gene expression of interferon and the JAK/STAT and TNFα/NFκB signaling pathways. Higher cell cycle activity and elevated levels of reactive oxygen species were confirmed in CD41hi HSCs by flow cytometry. Expression of Epcr, a marker for quiescent HSCs inversely correlated with expression of CD41 in mice, but did not show such reciprocal expression pattern in patients with MPN. Treatment with interferon-α further increased the frequency and percentage of CD41hi HSCs and reduced the number of JAK2-V617F+ HSCs in mice and patients with MPN. The shift toward the CD41hi subset of HSCs by interferon-α provides a possible mechanism of how interferon-α preferentially targets the JAK2 mutant clone.
650    _2
$a zvířata $7 D000818
650    _2
$a genový knockin $7 D055879
650    _2
$a hematopoetické kmenové buňky $x cytologie $x metabolismus $7 D006412
650    _2
$a lidé $7 D006801
650    _2
$a interferon alfa $x terapeutické užití $7 D016898
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a megakaryocyty $x cytologie $x metabolismus $7 D008533
650    _2
$a myši $7 D051379
650    _2
$a myši transgenní $7 D008822
650    _2
$a myeloproliferativní poruchy $x farmakoterapie $x genetika $7 D009196
650    _2
$a trombocytový membránový glykoprotein IIb $x genetika $7 D040201
650    _2
$a bodová mutace $x účinky léků $7 D017354
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hansen, Nils $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
700    1_
$a Stetka, Jan $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Luque Paz, Damien $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
700    1_
$a Kalmer, Milena $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschul (RWTH) Aachen University, Aachen, Germany
700    1_
$a Hilfiker, Julian $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
700    1_
$a Endele, Max $u Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
700    1_
$a Ahmed, Nouraiz $u Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
700    1_
$a Kubovcakova, Lucia $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
700    1_
$a Rybarikova, Margareta $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
700    1_
$a Hao-Shen, Hui $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
700    1_
$a Geier, Florian $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland $u Swiss Institute of Bioinformatics, Basel, Switzerland
700    1_
$a Beisel, Christian $u Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
700    1_
$a Dirnhofer, Stefan $u Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; and
700    1_
$a Schroeder, Timm $u Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland
700    1_
$a Brümmendorf, Tim H $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschul (RWTH) Aachen University, Aachen, Germany
700    1_
$a Wolf, Dominik $u Internal Medicine V, Department of Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
700    1_
$a Koschmieder, Steffen $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschul (RWTH) Aachen University, Aachen, Germany
700    1_
$a Skoda, Radek C $u Department of Biomedicine, Experimental Hematology, University Hospital Basel-University of Basel, Basel, Switzerland
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 137, č. 16 (2021), s. 2139-2151
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33667305 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133451 $b ABA008
999    __
$a ok $b bmc $g 1714752 $s 1146345
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 137 $c 16 $d 2139-2151 $e 20210422 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace